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Background: A large number of longitudinal studies of population-based ageing cohorts are in progress internationally,
but the insights from these studies into the risk and protective factors for cognitive ageing and conditions like mild
cognitive impairment and dementia have been inconsistent. Some of the problems confounding this research can be
reduced by harmonising and pooling data across studies. COSMIC (Cohort Studies of Memory in an International
Consortium) aims to harmonise data from international cohort studies of cognitive ageing, in order to better understand
the determinants of cognitive ageing and neurocognitive disorders.
Methods/Design: Longitudinal studies of cognitive ageing and dementia with at least 500 individuals aged 60 years or
over are eligible and invited to be members of COSMIC. There are currently 17 member studies, from regions that
include Asia, Australia, Europe, and North America. A Research Steering Committee has been established, two meetings
of study leaders held, and a website developed. The initial attempts at harmonising key variables like
neuropsychological test scores are in progress.
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Discussion: The challenges of international consortia like COSMIC include efficient communication among members,
extended use of resources, and data harmonisation. Successful harmonisation will facilitate projects investigating rates
of cognitive decline, risk and protective factors for mild cognitive impairment, and biomarkers of mild cognitive
impairment and dementia. Extended implications of COSMIC could include standardised ways of collecting and
reporting data, and a rich cognitive ageing database being made available to other researchers. COSMIC could
potentially transform our understanding of the epidemiology of cognitive ageing, and have a
world-wide impact on promoting successful ageing.
Keywords: Cohort studies, Cognitive ageing, Data harmonisation, Dementia, International consortium, Mild cognitive
impairmentBackground
The ageing of our populations, with the increasing preva-
lence of physical and cognitive disorders associated with
age, poses a major burden on society [1]. Making an im-
pact on this disability burden requires an understanding
of the risk and protective factors for age-related cog-
nitive decline, frailty and chronic disease. The optimal
approach to study this involves the longitudinal examin-
ation of population-based ageing cohorts. There are many
such studies currently ongoing internationally, but there is
considerable inconsistency in the results produced [2] and
further systematic examination of the existing evidence is
required to determine findings which are robust.
Some of the variation in prevalence rates and risk fac-
tors identified across studies may be associated with re-
gional and/or ethnic differences. For example, rates of
non-amnestic mild cognitive impairment (MCI) are re-
ported to be higher in blacks than whites from a similar
geographical location, even when controlling for sex and
education [3]. However, a significant proportion of the
variance between studies is likely attributable to differ-
ences in methodology, including differences in the assess-
ment tools and performance criteria used for diagnosing
cognitive disorders. Indeed, small but theoretically valid
changes to how objective cognitive impairment was oper-
ationally defined led to greatly elevated prevalence rates,
from 4% to 70% [4]. Similarly, using different criteria for
the diagnosis of dementia can result in vastly different
prevalence figures [5].
There are a number of approaches for overcoming
methodological differences and other sources of hetero-
geneity so that studies can be more accurately compared
and true differences identified. These include the use of
standardised protocols, meta-analysis, and harmonisa-
tion of data [6]. The use of standardised or even similar
protocols is a rare feature of existing collaborations (the
10/66 Dementia Research Group is one exception [7]),
and meta-analysis is limited to published results. In con-
trast, data harmonisation offers the potential to explore
both existing and novel research questions by a cost-
effective use of previously-collected data.Harmonising data across studies to create a single, large
database helps to minimise the influence of both study-
level (e.g., methodology) and individual level (e.g., demo-
graphic) factors, while also enabling these to be explored
as potential contributors to differences in results [8,9].
Other advantages include increased statistical power
for detecting effects, and the inherent replication and
enhanced generalisability associated with using heteroge-
neous samples and methodologies [8].
COSMIC (Cohort Studies of Memory in an International
Consortium) is a recently established endeavour that aims
to bring together cohort studies of cognitive ageing inter-
nationally in order to facilitate a better understanding of
the determinants of cognitive ageing and neurocognitive
disorders. The two main objectives of this project are to:
1. Harmonise shared, non-identifiable data from cohort
studies that longitudinally examine change in
cognitive function and the development of dementia
in older individuals (60+ years).
2. Perform joint or mega-analyses using combined,
harmonised data sets that yield collated results with
enhanced statistical power, in addition to comparisons
across geographical regions, ethnicities and
sociocultural groups.
Other collaborations bringing together cohort studies of
ageing include the genetics-focused CHARGE (Cohorts
for Heart and Aging Research in Genomic Epidemiology)
[10] and ENIGMA (Enhancing NeuroImaging Genetics
through Meta-Analysis) [11]. Consortia with a particu-
lar interest in cognitive ageing include the UK-based
HALCyon (Healthy Ageing across the Life Course) [12],
the primarily Europe-based CHANCES (Consortium on
Health and Ageing: Network of Cohorts in Europe and
the United States) [13], the Australian-based DYNOPTA
(Dynamic Analyses to Optimise Ageing) [14], and the
IALSA (Integrative Analysis of Longitudinal Studies on
Aging) network [15], which has member studies from
Europe, North America and Australia. None of these con-
sortia have any studies from Asia, where the current and
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to be greater than that of Europe and the Americas com-
bined [1]. COSMIC hopes to distinguish itself by being a
truly international effort comprising studies with a clinical
and biomedical focus from Asia, Europe, the Americas,
and Oceania. COSMIC was established in 2012, with pro-
gress reported in 2013 [16].
Methods/design
Membership
Studies are eligible to participate in COSMIC if they
meet the following membership criteria:
1. Are epidemiological, and therefore population-based.
2. Have a minimum sample size of 500.
3. Examine individuals aged 60 years and over.
4. Are longitudinal, with a minimum of two
assessments.
5. Include assessment of cognitive function as an
important, if not central, objective.
6. The outcome measures include dementia and/or
cognitive impairment and/or cognitive decline.
Official enrolment in COSMIC involves a lead investi-
gator having signed a memorandum of understanding
that entails a willingness to share non-identifiable raw
and/or processed data for joint or mega-analyses. Studies
that, for institutional or other reasons, are unable to
provide raw and/or processed data may participate in
COSMIC as provisional members, if willing to provide
results of in-house analyses conducted using COSMIC
protocols. At the time of writing there are 14 officially
enrolled and 3 provisional members of COSMIC. These
studies, and their key demographic characteristics, are
shown in Table 1. It is intended that the overall sample
size and range of geographical regions and ethnicities rep-
resented be extended even further, and thus we ask that
any study meeting the eligibility criteria consider contact-
ing us to become a member of COSMIC. Studies from
Africa, South America and Eastern Europe are particu-
larly encouraged to join.
Organisation
COSMIC has a Research Steering Committee comprising
one representative from each participating study, generally
the lead investigator or a delegate. The primary functions
of the Research Steering Committee are:
1. To develop guidelines for the inclusion and
exclusion of studies.
2. To provide rules of participation and guidelines for the
roles and responsibilities of the participating studies.
3. To approve Workgroups.
4. To select topics of interest.5. To provide overall analytic strategies.
6. To develop rules for publication, including
authorship.
7. To develop rules for the protection of intellectual
property, when relevant.
8. To seek funds to support COSMIC.
Meetings
An initial meeting of many (now member) study leaders
on July 16, 2012 in Vancouver supported the official estab-
lishment of COSMIC. Potential projects, both initial and
more long-term, and the steps needed to progress these
were among the topics discussed. A subsequent meeting
comprising many of the Research Steering Committee
members was held on July 15, 2013 in Boston.
Website
A website has been established that contains a de-
scription of COSMIC and summaries of the member
studies (http://www.cheba.unsw.edu.au/group/cosmic).
This website is intended to serve as an avenue for
presenting and preserving COSMIC project protocols
and results, and will potentially house data restricted by
password to COSMIC members. The Sydney team are
currently responsible for the development and mainten-
ance of the COSMIC website.
Ethics
The overall COSMIC project has been approved by the
Human Research Ethics Committee of the University of
New South Wales, Sydney. Member studies are respon-
sible for obtaining approval (if considered necessary)
from their local institutional review board for the sharing
of data. However, de-identified data are not considered
Protected Health information by the National Institute of
Health of the USA. A protocol for the de-identification of
data has been developed.
Discussion
Challenges
General challenges facing large, international consortia
have been previously described (e.g., by CHARGE [10]).
These include a potential need for additional funding to
prolong the use of study data beyond initial anticipa-
tions, and timely and effective communication among
members across different countries.
More specific to COSMIC are challenges associated with
harmonisation, many of which have also been previously
described [9,35]. The major challenge of harmonisation
stems from differences between studies in the measure-
ment instruments used and/or differences in how ques-
tions from similar instruments are worded and responses
provided and categorised, including the effect of language
and culture. Attempts to maximise the number of studies
Table 1 COSMIC member studies
Study Country Sample size Age range Males (%) Main races/ethnicities Start and
end date
Key reference(s)
Canadian Study of Health and Aging (CSHA) Canada 10263 65-102 43 Caucasian 1991-2002 CSHA Working Group (1994) [17]
Chinese Longitudinal Ageing Study (CLAS)* China 3514 60+ 44 Chinese 2010- Xiao et al. (2013) [18]
Cognitive Function and Ageing Studies (CFAS)† UK 13004 65+ 40 Caucasian 1991- Brayne et al. (2006) [19]
Einstein Aging Study (EAS)* USA 1956 66-104 39 Caucasian/African
American
1993- Katz et al. (2012) [3]
Etude Santé Psychologique Prévalence Risques et
Traitement (ESPRIT)*
France 2268 65+ 42 Not recorded 1999- Ritchie et al. (2010) [20]
Framingham Heart Study (FHS)† USA 15328‡ 5+ 50 Caucasian 1948- Dawber & Kannel (1958) [21];
Feinleib et al. (1975) [22];
Splansky et al. (2007) [23]
Hong Kong Memory and Ageing Prospective Study
(HK-MAPS)*
Hong Kong 787 60+ 46 Chinese 2005- Wong et al. (2013) [24]
Korean Longitudinal Study on Cognitive Aging and
Dementia (KLOSCAD)
South Korea 6479 60+ 44 Korean 2009- Kim et al. (2013) [25]
Mayo Clinic Study of Aging (MCSA)† USA 4000 50-89 50 Caucasian 2004- Roberts et al. (2008) [26]
Monongahela Valley Independent Elders Survey (MoVIES)* USA 1681 65+ 42 Caucasian 1987-2002 Ganguli et al. (2000) [27]
Personality and Total Health (PATH) Through Life Project* Australia 2551 60-64 52 Caucasian 2001- Anstey et al. (2012) [28]
Singapore Longitudinal Ageing Studies (SLAS) I and II* Singapore 5748 54-98 37 Chinese 2003- Feng et al. (2010, 2013) [29,30]
Sydney Memory and Ageing Study (Sydney MAS)* Australia 1037 70+ 45 Caucasian 2005- Sachdev et al. (2010) [31]
Tajiri Project Japan 1654 65+ 42 Japanese 1998-2005 Meguro et al. (2002) [32]
Washington Heights Inwood and Columbia Aging
Project (WHICAP)*
USA 4577 63-103 32 Hispanic/African
American/Caucasian
1989- Tang et al. (2001) [33]
ZARADEMP Project (ZARAgoza DEMentia DEPression Project)* Spain 4803 55+ 42 Caucasian 1994- Lobo et al. (2005) [34]
*Data for the first project have been made available.
†Provisional member.
‡Including 3 generations (Original cohort, Offspring, Grandchildren) and separate Omni cohort of 900 ethnic minority participants.
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formation from some studies be simplified (e.g., converted
from a continuous measure to a categorical scale). There is
a potential reduction in validity involved in simplifying
data, but there are mechanisms by which this can be tested
and/or quantified [9].
Meeting the objectives of COSMIC will require various
data types to be harmonised, but data relating to cognitive
outcomes such as impairment and decline are likely to be
the most challenging (i.e., more so than demographic and
health-related variables). COSMIC member studies have
operationally defined cognitive outcomes in vastly differ-
ent ways. For example, for the purposes of diagnosing
MCI, cognitive impairment has been variously defined
as abnormal scores on the memory items of two cogni-
tive status instruments (Mini-Mental State Examination
and Geriatric Mental State Schedule) in the Zaragoza
Dementia Depression Project [36], and as a score on any
measure from a comprehensive neuropsychological bat-
tery 1.5 or more standard deviations below published nor-
mative values in the Sydney Memory and Ageing Study
[31]. Different studies have used different neuropsycho-
logical test batteries, but even when similar cognitive tests
have been used it is often the case that different versions
have been used or the tests have been administered in a
non-standard way. An added complication is the need to
reconcile differences in the data while giving appropriate
consideration to relevant demographic effects, including
those associated with gender and education.
First project
The aim of the first COSMIC project is to compare the
baseline prevalence of MCI across the COSMIC member
cohorts and the different regions and ethnicities repre-
sented by these. The project is currently underway, and
is being coordinated by the Sydney team. A question-
naire was developed and promulgated, with the informa-
tion provided guiding a subsequent request for data
from the studies on:
1. Demographics.
2. Sample representativeness.
3. Neuropsychological test performance.
4. Functional test scores.
5. Memory/cognitive complain/concerns.
6. Criteria used for MCI.
The receipt of data was followed by communication
with data managers and/or study leaders to clarify the na-
ture of data (e.g., the particular neuropsychological test
used or manner of administration) and/or to ask that fur-
ther data be provided (e.g., the individual items from a
functional test scale in addition to a total score originally
provided). Data from 11 studies have been made availablefor this project (see Table 1), and there is a total sample
size of more than 23,000 non-demented individuals aged
60 and older.
Some demographic variables have been harmonised. All
studies provided age in years, and harmonising sex only
required some recoding to a common scale (female = 0;
male = 1). Education was less straightforward. A four-level
categorical scale of the highest level of education achieved
(Less than high school completion, High school comple-
tion, Technical or college diploma, University degree) was
chosen as the most appropriate common measure, and to
which various other categorical formats or years of formal
education were transformed (see Additional file 1 for the
protocol). Data were provided in the harmonised format
by the studies themselves, or later transformed from the
original variable by the project coordinators.
The next step will be to harmonise the data needed to
make classifications of MCI. The participating studies
have published widely varying rates of MCI, from as low
as 3.2% for the Monongahela Valley Independent Elders
Survey [37] to 34.8% for the Sydney Memory and Ageing
Study [31]. Differences between the studies in how MCI
diagnoses were made have undoubtedly contributed to
the varying prevalence rates [4], and minimising this re-
quires the harmonisation of data informing the four gen-
erally accepted criteria for MCI:
1. Absence of dementia.
2. No or minimal functional impairment.
3. Objective cognitive impairment.
4. Memory complaint or concern [38,39].
Future projects
A number of future projects utilising COSMIC data are
currently planned, and aim to make comparisons across
COSMIC cohorts, countries and ethnic groups of:
1. Risk and protective factors for MCI.
2. Rates of cognitive decline.
3. Biomarkers (e.g., blood, genetic and MRI-derived) of
MCI and dementia.
Many of the existing member studies have relevant
data to contribute to these projects. It is expected that
additional projects will address more refined and specific
topics addressing the overall objectives of COSMIC.
This could include identifying and comparing rates of
decline within particular cognitive domains, and estab-
lishing associations between untreated hypertension or
non-traditional risk factors and cognitive decline. Pro-
jects like these will be enabled and facilitated by growing
the COSMIC membership base to ensure that there are
sufficient relevant data on variables not collected by
all studies.
Sachdev et al. BMC Neurology 2013, 13:165 Page 6 of 8
http://www.biomedcentral.com/1471-2377/13/165Extended Implications of COSMIC
The mechanisms for harmonising measures developed
by COSMIC could produce standardised ways of collect-
ing and reporting data that facilitate the comparability of
longitudinal studies of ageing. This includes previous or
existing studies, for which data could be reformatted
and further analysed. It may also guide the choice of
measures used or type of data collected by future stud-
ies, for which the capacity to directly compare results
with those of many other cohorts would greatly enhance
their interpretability and relevance.
There is also the potential for the COSMIC database
to be made available to non-consortium researchers via
the website, following consortia-based publications and
with the approval of the Research Steering Committee.
The scientific benefits of making large databases avail-
able to researchers worldwide are demonstrated by the
more than 250 publications reported to have arisen from
the sharing of ADNI (Alzheimer's Disease Neuroimaging
Initiative) data across the internet [40].
With these, and potentially further extended implica-
tions and uses of COSMIC data, member studies can be
confident that their data are being fully utilised and that
they are contributing to a truly global effort to under-
stand and combat the problems associated with cogni-
tive ageing, MCI and dementia.
Conclusion
The COSMIC project is a truly international effort to in-
form the epidemiology of cognitive disorders associated
with advanced age by identifying risk factors and bio-
markers that are common as well as unique. It has the po-
tential to transform our understanding of the epidemiology
of cognitive ageing and have a world-wide impact on pro-
moting successful ageing.
Additional file
Additional file 1: Protocol for harmonising education across
COSMIC member studies participating in the first project.
Abbreviations
COSMIC: Cohort Studies of Memory in an International Consortium; MCI: Mild
cognitive impairment.
Competing interests
The authors declare that they have no competing interests, except for
Kenneth Rockwood: Founder and shareholder of DGI Clinical; Richard Lipton
and Mindy Katz have received monies from Bristol Myers Squibb Inc.; Ronald
Petersen is on the Data Monitoring Boards of Pfizer Inc. and Janssen
Alzheimer Immunotherapy, and a consultant to GE Healthcare; Rosebud
Roberts has received a grant from Abbott Laboratories; Yaakov Stern is on
the Advisory Boards of Janssen LLC, Pfizer Inc., Alzheimer’s Association and
AbbVie, and has received Research Support from Piramal Research.
Authors’ contributions
PSS is the instigator and head of COSMIC, and together with DML drafted
the manuscript. All authors contributed to their local study, contributed tocritically revising the manuscript for important intellectual content, and
approved the final version of the manuscript for submission.
Acknowledgements
Canadian Study of Health and Aging (CSHA): Kenneth Rockwood (study
leader). Funding from the National Health Research Development Program
of Health Canada (6605-3954-MC[S]).
Chinese Longitudinal Ageing Study (CLAS): Shifu Xiao (study leader), Juan Li,
Xia Li. The authors extend their thanks to the main investigators from across
the different regions of China: Tao Wang, Muni Tang, Wei Chen, Feng Bao,
Huali Wang, Yuping Wang, Ying Liu, Yaping Wang, Yefeng Yuan, Xiaoyun
Zuo, Zhongming Chen, Xulai Zhang, Lijuan Cui, Wenyuan Wu, Mingyuan
Zhang. Funding from a China Ministry of Science and Technology grant
(2009BAI77B03).
Cognitive Function and Ageing Studies (CFAS): Carol Brayne (study leader),
Fiona E Matthews, Blossom CM Stephan. Funding from major awards from
the Medical Research Council and the Department of Health, UK.
Einstein Aging Study (EAS): Richard B Lipton (study leader), Mindy J Katz
(study leader). The authors acknowledge the contributions of Molly
Zimmerman and Carol Derby. Funding from National Institute on Health/
National Institute on Aging grants: 5P01 AG003949, 1R03 AG045474.
Etude Santé Psychologique Prévalence Risques et Traitement (ESPRIT): Karen
Ritchie (study leader), Isabelle Carrière, Marie-Laure Ancelin (study leader).
Funding from Novartis.
Framingham Heart Study (FHS): Sudha Seshadri (study leader), Rhoda Au,
Alexa S Beiser. The authors acknowledge the contributions of Philip A. Wolf
and Galit A. Weinstein, and the dedication of the FHS participants. Funding
from the National Heart, Lung and Blood Institute's Framingham Heart Study
(Contract No. N01-HC-25195) and grants from the National Institute of Aging
(AG08122, AG16495, AG033193), the National Institute of Neurological
Disorders and Stroke (NS17950), and the National Heart, Lung and Blood
Association (HL93029, U01HL 096917). The content is solely the responsibility
of the authors and does not necessarily represent the official views of the
National Institute of Neurological Disorders and Stroke, the National Heart
Lung and Blood Institute, the National Institute of Aging or the National Insti-
tutes of Health.
Hong Kong Memory and Ageing Prospective Study (HK-MAPS): Linda CW Lam
(study leader), Candy HY Wong, Ada WT Fung. The authors acknowledge the
contributions of Grace T.Y. Leung, Wai Chi Chan, Department of Health of
Hong Kong SAR, the participants and the social centers for their assistance in
the assessment, and thank Novartis and Astra Zeneca for their sponsorship
of souvenirs for the participants in the baseline study. The baseline study is
funded in part by the Mr. Lai Seung Hung & Mrs. Lai Chan Pui Ngong
Dementia in Hong Kong Research Fund, and by an educational fund from
Eisai.
Korean Longitudinal Study on Cognitive Aging and Dementia (KLOSCAD): Ki
Woong Kim (study leader), Ji Won Han, Tae Hui Kim. Funding from a Korean
Health Technology R&D Project grant from the Ministry for Health, Welfare, &
Family Affairs, Republic of Korea (Grant No. A092077).
Mayo Clinic Study of Aging (MCSA): Ronald C Petersen (study leader), Rosebud
O Roberts, Michelle M Mielke. Funding from the National Institute on Aging:
U01 AG006786, P50 AG016574, R01 AG034676.
Monongahela Valley Independent Elders Survey (MoVIES): Mary Ganguli (study
leader), Hiroko H Dodge, Tiffany Hughes. The authors acknowledge the
contributions of 1681 study participants from the Monongahela Valley and
of multiple MoVIES project personnel over the years. Funding from Grant #
R01AG07562 from the National Institute on Aging, National Institutes of
Health, United States Department of Health and Human Services.
Personality and Total Health (PATH) Through Life Project: Kaarin J Anstey
(study leader), Nicolas Cherbuin, Peter Butterworth. The authors acknowledge
the further study members Helen Christensen, Andrew MacKinnon, Simon
Easteal, Project Managers Trish Jacomb, Karen Maxwell, participants and the
NHMRC. Funding from National Health and Medical Research Council of
Australia grants 973302, 179805, 157125 and 1002160.
Singapore Longitudinal Ageing Studies (SLAS) I and II: Tze Pin Ng (study
leader), Qi Gao. The authors gratefully thank the help and support of the
following voluntary welfare organizations: Geylang East Home for the Aged,
Presbysterian Community Services, Thye Hua Kwan Moral Society (Moral
Neighbourhood Links), Yuhua Neighbourhood Link, Henderson Senior
Citizens’ Home, NTUC Eldercare Co-op Ltd, Thong Kheng Seniors Activity
Centre (Queenstown Centre) and Redhill Moral Seniors Activity Centre.
Sachdev et al. BMC Neurology 2013, 13:165 Page 7 of 8
http://www.biomedcentral.com/1471-2377/13/165Funding from research grants (No. 03/121/17/214 and No. 08/1/21/19/567)
from the Biomedical Research Council, Agency for Science, Technology and
Research (A*STAR) in Singapore.
Sydney Memory and Ageing Study (MAS): Perminder S Sachdev (study leader
and consortium head), Darren M Lipnicki, Nicole A Kochan, John D Crawford,
Simone Reppermund, Henry Brodaty (study leader). The authors
acknowledge the contributions of members of the MAS Team: Allison
Bowman, Kim Burns, Anthony Broe, Joula Dekker, Louise Dooley, Michele de
Permentier, Sarah Fairjones, Janelle Fletcher, Therese French, Cathy Foster,
Emma Nugent-Cleary-Fox, Chien Gooi, Evelyn Harvey, Rebecca Helyer,
Sharpley Hsieh, Laura Hughes, Sarah Jacek, Mary Johnston, Donna McCade,
Samantha Meeth, Eveline Milne, Angharad Moir, Ros O’Grady, Kia Pfaeffli,
Carine Pose, Laura Reuser, Amanda Rose, Peter Schofield, Zeeshan Shahnawaz,
Amanda Sharpley, Claire Thompson, Wiebke Queisser, and Sam Wong. Funding
from a National Health & Medical Research Council of Australia Program Grant
(ID 350833).
Tajiri Project: Kenichi Meguro (study leader). The author acknowledges the
contributions of Mari Kasai, Kei Nakamura, and Masahiro Nakatsuka.
Washington Heights Inwood and Columbia Aging Project (WHICAP): Nicole
Schupf (study leader), Jennifer Manly, Yaakov Stern. The authors
acknowledge the contributions of Richard Mayeux, Principal Investigator of
the WHICAP study, co-investigators Adam Brickman and Jose Luchsinger,
and study team members Danurys Sanchez, Ming X. Tang and Howard
Andrews. Funding from the National Institute of Health/National Institute on
Aging: Grants # R01 AG037212, P01 AG07232.
ZARADEMP Project (ZARAgoza DEMentia DEPression Project): Antonio Lobo
(study leader), Raúl Lopez-Anton, Javier Santabárbara. The authors acknowledge
the further study members Guillermo Marcos, Concepción De-la-Cámara, Pedro
Saz, Tirso Ventura, Miguel Angel Quintanilla, and Elena Lobo, and the
contributions of the ZARADEMP Workgroup who participated in the study.
Funding from the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III,
Spanish Ministry of Health, Madrid, Spain (grants 94/1562, 97/1321E, 98/0103,
01/0255, 03/0815, 06/0617, and G03/128) and Pfizer Foundation, Madrid.
Author details
1Centre for Healthy Brain Ageing, University of New South Wales, Sydney,
Australia. 2Dementia Collaborative Research Centre, University of New South
Wales, Sydney, Australia. 3Department of Medicine (Geriatric Medicine &
Neurology), Dalhousie University, Halifax, NS, Canada. 4Department of
Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiaotong
University School of Medicine, Shanghai, China. 5Institute of Psychology,
Chinese Academy of Sciences, Beijing, China. 6Department of Public Health
and Primary Care, Cambridge University, Cambridge, UK. 7MRC Biostatistics
Unit, Institute of Public Health, Cambridge, UK. 8Institute of Health and
Society, Newcastle University, Newcastle upon Tyne, UK. 9Saul B. Korey
Department of Neurology; Albert Einstein College of Medicine, Yeshiva
University, New York, NY, USA. 10Department of Epidemiology and
Population Health, Albert Einstein College of Medicine, Yeshiva University,
New York, NY, USA. 11Inserm, U1061 Nervous System Pathologies:
Epidemiological and Clinical Research, La Colombière Hospital, Montpellier
Cedex 5, France. 12Université de Montpellier 1, Montpellier, France. 13Faculty
of Medicine, Imperial College, St Mary’s Hospital, London, UK. 14Department
of Neurology, Boston University School of Medicine, Boston, MA, USA.
15Department of Biostatistics, Boston University School of Public Health,
Boston, MA, USA. 16Department of Psychiatry, The Chinese University of
Hong Kong, Hong Kong, SAR, China. 17Department of Psychiatry, Tai Po
Hospital, Hong Kong, SAR, China. 18Department of Neuropsychiatry, Seoul
National University Bundang Hospital, Seongnam, Korea. 19Department of
Psychiatry, Seoul National University College of Medicine, Seoul, Korea.
20Department of Brain and Cognitive Sciences, Seoul National University
College of Natural Sciences, Seoul, Korea. 21Mayo Clinic College of Medicine,
Rochester, MN, USA. 22Department of Psychiatry, University of Pittsburgh
School of Medicine, Pittsburgh, PA, USA. 23Department of Neurology,
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
24Department of Epidemiology, University of Pittsburgh Graduate School of
Public Health, Pittsburgh, PA, USA. 25Department of Neurology, Oregon
Health and Science University, Portland, OR, USA. 26Department of
Neurology, University of Michigan, Ann Arbor, MI, USA. 27Centre for Research
on Ageing, Health and Wellbeing, College of Medicine, Biology and
Environment, The Australian National University, Canberra, Australia.
28Gerontology Research Programme, Department of Psychological Medicine,Yong Loo Lin School of Medicine, National University of Singapore,
Singapore. 29Department of Geriatric Behavioral Neurology, Tohoku
University Graduate School of Medicine, Sendai, Japan. 30The Taub Institute
for Research in Alzheimer’s Disease and the Aging Brain, Columbia University,
New York, NY, USA. 31The Gertrude H. Sergievsky Center, Columbia
University, New York, NY, USA. 32The Division of Epidemiology, Joseph P.
Mailman School of Public Health, Columbia University, New York, NY, USA.
33The Department of Neurology, Columbia University, New York, NY, USA.
34Department of Medicine and Psychiatry, Universidad de Zaragoza,
Zaragoza, Spain. 35Centro de Investigación Biomédica en Red de Salud
Mental (CIBERSAM), Ministry of Science and Innovation, Madrid, Spain.
36Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain.
37Department of Psychology and Sociology, Universidad de Zaragoza,
Zaragoza, Spain. 38Department of Preventive Medicine and Public Health,
Universidad de Zaragoza, Zaragoza, Spain.
Received: 10 October 2013 Accepted: 31 October 2013
Published: 6 November 2013References
1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP: The global
prevalence of dementia: a systematic review and metaanalysis.
Alzheimers Dement 2013, 9:63–75. e62.
2. Plassman BL, Williams JW Jr, Burke JR, Holsinger T, Benjamin S: Systematic
review: factors associated with risk for and possible prevention of
cognitive decline in later life. Ann Intern Med 2010, 153:182–193.
3. Katz MJ, Lipton RB, Hall CB, Zimmerman ME, Sanders AE, Verghese J,
Dickson DW, Derby CA: Age-specific and sex-specific prevalence and
incidence of mild cognitive impairment, dementia, and Alzheimer
dementia in blacks and whites: a report from the Einstein Aging Study.
Alzheimer Dis Assoc Disord 2012, 26:335–343.
4. Kochan NA, Slavin MJ, Brodaty H, Crawford JD, Trollor JN, Draper B, Sachdev
PS: Effect of different impairment criteria on prevalence of "objective"
mild cognitive impairment in a community sample. Am J Geriatr
Psychiatry 2010, 18:711–722.
5. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V: The effect of different
diagnostic criteria on the prevalence of dementia. N Engl J Med 1997,
337:1667–1674.
6. Beer-Borst S, Morabia A, Hercberg S, Vitek O, Bernstein MS, Galan P, Galasso
R, Giampaoli S, Houterman S, McCrum E, et al: Obesity and other health
determinants across Europe: the EURALIM project. J Epidemiol Community
Health 2000, 54:424–430.
7. Prince M, Ferri CP, Acosta D, Albanese E, Arizaga R, Dewey M, Gavrilova SI,
Guerra M, Huang Y, Jacob KS, et al: The protocols for the 10/66 dementia
research group population-based research programme. BMC Public Health
2007, 7:165.
8. Hofer SM, Piccinin AM: Integrative data analysis through coordination of
measurement and analysis protocol across independent longitudinal
studies. Psychol Methods 2009, 14:150–164.
9. Schaap LA, Peeters GM, Dennison EM, Zambon S, Nikolaus T, Sanchez-
Martinez M, Musacchio E, van Schoor NM, Deeg DJ: European Project on
OSteoArthritis (EPOSA): methodological challenges in harmonization of
existing data from five European population-based cohorts on aging.
BMC Musculoskelet Disord 2011, 12:272.
10. CHARGE (Cohorts for Heart and Aging Research in Genomic
Epidemiology). [http://web.chargeconsortium.com]
11. ENIGMA (Enhancing NeuroImaging Genetics through Meta-Analysis).
[http://enigma.loni.ucla.edu]
12. HALCyon (Healthy Ageing across the Life Course). [http://www.halcyon.ac.uk]
13. CHANCES (Consortium on Health and Ageing: Network of Cohorts in
Europe and the United States). [http://www.chancesfp7.eu]
14. Anstey KJ, Byles JE, Luszcz MA, Mitchell P, Steel D, Booth H, Browning C,
Butterworth P, Cumming RG, Healy J, et al: Cohort profile: The Dynamic
Analyses to Optimize Ageing (DYNOPTA) project. Int J Epidemiol 2010,
39:44–51.
15. IALSA (Integrative Analysis of Longitudinal Studies on Aging).
[http://web.uvic.ca/~ilife]
16. Sachdev P, Lipnicki D, Kochan N, Crawford J: COSMIC: Cohort Studies of
Memory in an International Consortium [abstract]. Alzheimers Dement
2013, 9(Suppl 4):P611.
Sachdev et al. BMC Neurology 2013, 13:165 Page 8 of 8
http://www.biomedcentral.com/1471-2377/13/16517. Canadian Study of Health and Aging Working Group: Canadian study of
health and aging: study methods and prevalence of dementia.
CMAJ 1994, 150:899–913.
18. Xiao S, Li J, Tang M, Chen W, Bao F, Wang H, Wang Y, Liu Y, Wang Y,
Yuan Y, et al: Methodology of China’s national study on the evaluation,
early recognition, and treatment of psychological problems in the
elderly: the China Longitudinal Aging Study. Shanghai Archives of
Psychiatry 2013, 25:91–97.
19. Brayne C, McCracken C, Matthews FE: Cohort profile: the Medical Research
Council Cognitive Function and Ageing Study (CFAS). Int J Epidemiol 2006,
35:1140–1145.
20. Ritchie K, Carriere I, Ritchie CW, Berr C, Artero S, Ancelin ML: Designing
prevention programmes to reduce incidence of dementia: prospective
cohort study of modifiable risk factors. BMJ 2010, 341:c3885.
21. Dawber TR, Kannel WB: An epidemiologic study of heart disease: the
Framingham study. Nutr Rev 1958, 16:1–4.
22. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP: The
Framingham Offspring Study. Design and preliminary data. Prev Med 1975,
4:518–525.
23. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ,
D'Agostino RB Sr, Fox CS, Larson MG, Murabito JM, et al: The Third
Generation Cohort of the National Heart, Lung, and Blood Institute's
Framingham Heart Study: design, recruitment, and initial examination.
Am J Epidemiol 2007, 165:1328–1335.
24. Wong CH, Leung GT, Fung AW, Chan WC, Lam LC: Cognitive predictors for
five-year conversion to dementia in community-dwelling Chinese older
adults. Int Psychogeriatr 2013, 25:1125–1134.
25. Kim TH, Park JH, Lee JJ, Jhoo JH, Kim BJ, Kim JL, Kim SG, Youn JC, Ryu SH,
Lee DY, et al: Overview of the Korean Longitudinal Study on Cognitive
Aging and Dementia [abstract]. Alzheimers Dement 2013,
9(Suppl 4):626–627.
26. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ,
Tangalos EG, Petersen RC, Rocca WA: The Mayo Clinic Study of Aging:
design and sampling, participation, baseline measures and sample
characteristics. Neuroepidemiology 2008, 30:58–69.
27. Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST: Ten-year incidence of
dementia in a rural elderly US community population: the MoVIES
Project. Neurology 2000, 54:1109–1116.
28. Anstey KJ, Christensen H, Butterworth P, Easteal S, Mackinnon A, Jacomb T,
Maxwell K, Rodgers B, Windsor T, Cherbuin N, et al: Cohort profile: the
PATH through life project. Int J Epidemiol 2012, 41:951–960.
29. Feng L, Chong MS, Lim WS, Lee TS, Collinson SL, Yap P, Ng TP: Metabolic
syndrome and amnestic mild cognitive impairment: singapore
longitudinal ageing study-2 findings. J Alzheimers Dis 2013, 34:649–657.
30. Feng L, Gwee X, Kua EH, Ng TP: Cognitive function and tea consumption
in community dwelling older Chinese in Singapore. J Nutr Health Aging 2010,
14:433–438.
31. Sachdev PS, Brodaty H, Reppermund S, Kochan NA, Trollor JN, Draper B,
Slavin MJ, Crawford J, Kang K, Broe GA, et al: The Sydney Memory and
Ageing Study (MAS): methodology and baseline medical and
neuropsychiatric characteristics of an elderly epidemiological
non-demented cohort of Australians aged 70–90 years. Int Psychogeriatr
2010, 22:1248–1264.
32. Meguro K, Ishii H, Yamaguchi S, Ishizaki J, Shimada M, Sato M, Hashimoto R,
Shimada Y, Meguro M, Yamadori A, et al: Prevalence of dementia and
dementing diseases in Japan: the Tajiri project. Arch Neurol 2002,
59:1109–1114.
33. Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, Merchant C,
Lantigua R, Costa R, Stern Y, et al: Incidence of AD in African-Americans,
Caribbean Hispanics, and Caucasians in northern Manhattan.
Neurology 2001, 56:49–56.
34. Lobo A, Saz P, Marcos G, Día J-L, De-la-Cámara C, Ventura T, Montañés JA,
Lobo-Escolar A, Aznar S: The ZARADEMP Project on the incidence,
prevalence and risk factors of dementia (and depression) in the elderly
community: II Methods and first results. Eur J Psychiatry 2005, 19:40–54.
35. Pluijm SM, Bardage C, Nikula S, Blumstein T, Jylha M, Minicuci N,
Zunzunegui MV, Pedersen NL, Deeg DJ: A harmonized measure of
activities of daily living was a reliable and valid instrument for
comparing disability in older people across countries. J Clin Epidemiol
2005, 58:1015–1023.36. Lobo A, Lopez-Anton R, De-la-Camara C, Quintanilla MA, Campayo A, Saz P:
Non-cognitive psychopathological symptoms associated with incident mild
cognitive impairment and dementia, Alzheimer's type. Neurotox Res 2008,
14:263–272.
37. Ganguli M, Dodge HH, Shen C, DeKosky ST: Mild cognitive impairment,
amnestic type: an epidemiologic study. Neurology 2004, 63:115–121.
38. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern
Med 2004, 256:183–194.
39. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A,
Backman L, Albert M, Almkvist O, et al: Mild cognitive impairment–beyond
controversies, towards a consensus: report of the International Working
Group on Mild Cognitive Impairment. J Intern Med 2004, 256:240–246.
40. Carrillo MC, Bain LJ, Frisoni GB, Weiner MW: Worldwide Alzheimer's disease
neuroimaging initiative. Alzheimers Dement 2012, 8:337–342.
doi:10.1186/1471-2377-13-165
Cite this article as: Sachdev et al.: COSMIC (Cohort Studies of Memory in
an International Consortium): An international consortium to identify
risk and protective factors and biomarkers of cognitive ageing and
dementia in diverse ethnic and sociocultural groups. BMC Neurology
2013 13:165.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
